Passage BIO, Inc. — Form SCHEDULE 13D
Filed July 2, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 28/100
What the filing says
On June 25, 2026, Lynx1 Capital Management LP and Weston Nichols purchased 50,055 shares of Passage BIO common stock in open-market transactions at a weighted average price of $4.1175 per share (price range $3.33–$4.30), totaling approximately $206,295. A joint Schedule 13D filing was submitted July 2, 2026.
Why this rating
50K shares (~2.5% of capitalization at $25.4M valuation); typical passive accumulation. No control threshold or strategic signal disclosed.
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.